Bruce Maniet, DO
Family Medicine · Bells, TXNPI 1568449825
Payments from drug & device makers
Across 277 payments — averaging $31.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- AbbVie$1K
- Johnson & Johnson$878
- AstraZeneca$765
- Abbott$577
- Novo Nordisk$560
- plus $3K from 28 others
What the payments were for
- Food & beverage$8,709100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 41 | $2,060 |
| AbbVie | 38 | $1,122 |
| Johnson & Johnson | 40 | $878 |
| AstraZeneca | 19 | $765 |
| Abbott | 11 | $577 |
| Novo Nordisk | 5 | $560 |
| Lilly USA, LLC | 21 | $430 |
| Bayer | 5 | $403 |
| Otsuka America Pharmaceutical, Inc. | 13 | $238 |
| Eisai Inc. | 6 | $222 |
| Sunovion Pharmaceuticals Inc. | 18 | $184 |
| Merck | 5 | $155 |
| Sun Pharmaceutical Industries Inc. | 3 | $125 |
| Boehringer Ingelheim | 3 | $111 |
| Heartflow, Inc. | 5 | $107 |
| Mylan Specialty L.p. | 6 | $101 |
| Bioventus LLC | 5 | $100 |
| Pfizer | 6 | $97 |
| Axsome Therapeutics, Inc. | 3 | $61 |
| Avanir Pharmaceuticals, Inc. | 4 | $59 |
| Scpharmaceuticals Inc. | 3 | $54 |
| Dexcom, Inc. | 2 | $44 |
| Corium, LLC | 2 | $36 |
| CMP Pharma, Inc. | 2 | $33 |
| GSK | 2 | $32 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Organon | 1 | $22 |
| SK Life Science, Inc. | 1 | $22 |
| Medtronic | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Exact Sciences | 1 | $18 |
| Axonics, Inc. | 1 | $18 |
| Gilead | 1 | $14 |
| Assertio Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,720 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 351 | $193,059 |
| OzempicSemaglutide | 136 | $135,682 |
| FarxigaDapagliflozin Propanediol | 101 | $71,978 |
| TrulicityDulaglutide | 41 | $64,740 |
| MounjaroTirzepatide | 57 | $63,983 |
| XareltoRivaroxaban | 68 | $42,095 |
| LinzessLinaclotide | 59 | $38,754 |
| Repatha SureclickEvolocumab | 51 | $32,331 |
| JardianceEmpagliflozin | 44 | $30,645 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $26,275 |
| EntrestoSacubitril/Valsartan | 19 | $17,977 |
| MyrbetriqMirabegron | 38 | $14,921 |
| RexultiBrexpiprazole | 11 | $13,245 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $12,682 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $12,273 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $97 | $193,059351 claims |
| Novo NordiskOzempic | $560 | $135,682136 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $430 | $128,72398 claims |
| AstraZenecaFarxiga, Symbicort | $765 | $78,803128 claims |
| AbbVieLinzess, Namzaric | $1,122 | $50,97281 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $111 | $47,01068 claims |
| Johnson & JohnsonXarelto | $878 | $42,09568 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $32 | $38,95757 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $238 | $13,24511 claims |
| MerckJanumet | $155 | $12,27316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Bells
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.